Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alpha Tau Medical Ltd. - SIC # 3840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
DRTS
Nasdaq
3840
www.alphatau.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alpha Tau Medical Ltd.
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
- Feb 3rd, 2025 1:30 pm
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
- Jan 27th, 2025 2:00 pm
US Penny Stocks To Consider In January 2025
- Jan 8th, 2025 1:09 pm
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
- Dec 18th, 2024 1:30 pm
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
- Dec 17th, 2024 2:00 pm
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec 11th, 2024 1:30 pm
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
- Dec 6th, 2024 1:30 pm
3 Promising Penny Stocks In The US With Market Caps Under $400M
- Dec 2nd, 2024 12:09 am
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov 19th, 2024 9:00 pm
Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference
- Nov 13th, 2024 1:30 pm
Discover Alpha Tau Medical And 2 Other US Penny Stocks
- Nov 1st, 2024 5:07 pm
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
- Oct 21st, 2024 12:30 pm
Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment
- Oct 11th, 2024 12:57 pm
Alpha Tau Treats First Patient with Recurrent Lung Cancer
- Oct 10th, 2024 12:30 pm
FDA approves study of Alpha Tau’s Alpha DaRT for recurrent cSCC treatment
- Sep 23rd, 2024 10:52 am
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
- Sep 20th, 2024 12:30 pm
Sidoti Events, LLC's Virtual September Small-Cap Conference
- Sep 17th, 2024 12:00 pm
DRTS: Company Seeks to Develop Significant Advance in Cancer Therapy with Alpha DaRT
- Sep 3rd, 2024 12:42 pm
Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
- Aug 22nd, 2024 12:30 pm
Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Aug 14th, 2024 8:02 pm
Scroll